Roche struck two deals tied to antibody‑drug conjugates this week: a headline license for Hansoh Pharma’s early‑stage CDH17‑targeting ADC with up to $1.45 billion in downstream payments, and a disclosed $80 million upfront component tied to that program. The agreements give Roche global rights to develop, manufacture and commercialize the candidate for colorectal cancer and potentially other indications. Hansoh and Roche framed the pact as a fast route to advance an early ADC into global development while aligning milestone incentives across development and commercialization.